Claims
- 1. A method for preventing photoaging in human skin, by administering an EGF-R protein tyrosine kinase inhibitor to the human whose skin is exposed to UV radiation.
- 2. The method of claim 1, wherein the administration is topical.
- 3. The method of claim 1, wherein the administration is prior to exposure to UV radiation.
- 4. The method of claim 3, wherein the administration is at least six (6) hours prior to exposure.
- 5. The method of claim 1, wherein the tyrosine kinase inhibitor is selected from the group consisting of isoflavones, suramin sodium (and related derivatives), heribimycin-A, lavendustin-A, erbstatin, benzylidenemalononitriles, brominated quinazolines, tyrphostins, phenylaminopyridines, pyrazolopyrimidines, pyrrolopyrimidines, thioindoles, dianilinopthalimides, anthraquinones, and mixutres thereof.
- 6. The method of claim 4, further comprising administering a retinoid.
- 7. The method of claim 5, wherein the isoflavone is genistein or quercetin.
- 8. A composition for preventing induction of MMPs in human skin due to exposure of the skin to UV radiation, comprising an EGF-R protein tyrosine kinase inhibitor admixed in a dermatologically suitable carrier therefor.
- 9. The composition of claim 8, further comprising at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, antioxidants, UV sunscreens, and compatible mixtures thereof.
- 10. The composition of claim 9, comprising a UVA blocker and a UVB blocker, and at least one additional compound selected from the group consisting of retinoids, P-450 inhibitors, and antioxidants, and compatible mixtures thereof.
- 11. The composition of claim 10, wherein the additional compound is a retinoid.
- 12. The composition of claim 11, wherein the retinoid is retinol.
- 13. A composition for preventing induction of MMPs in human skin due to exposure of the skin to UV radiation, comprising an EGF-R protein tyrosine kinase inhibitor and a retinoid admixed in a dermatologically suitable carrier therefor.
- 14. The composition of claim 13, wherein the retinoid is retinol or retinoic acid.
- 15. The composition of claim 13, wherein the EGF-R inhibitor is an isoflavone.
- 16. The composition of claim 15, wherein the isoflavone is genistein.
RELATED APPLICATIONS
[0001] This application is based on provisional application No. 60/213940, filed Jun. 26, 2000, the disclosure and figures of which are incorporated herein in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60213940 |
Jun 2000 |
US |